TISIDB

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cytoplasm, cytoskeleton Note=Microtubule-associated.
Domain	PF01031 Dynamin central region PF00350 Dynamin family PF02212 Dynamin GTPase effector domain PF00169 PH domain
Function	Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Most probably involved in vesicular trafficking processes. Involved in receptor-mediated endocytosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000266 mitochondrial fission GO:0002029 desensitization of G-protein coupled receptor protein signaling pathway GO:0002031 G-protein coupled receptor internalization GO:0003373 dynamin family protein polymerization involved in membrane fission GO:0003374 dynamin family protein polymerization involved in mitochondrial fission GO:0006898 receptor-mediated endocytosis GO:0007032 endosome organization GO:0007033 vacuole organization GO:0007270 neuron-neuron synaptic transmission GO:0007605 sensory perception of sound GO:0007626 locomotory behavior GO:0008277 regulation of G-protein coupled receptor protein signaling pathway GO:0008344 adult locomotory behavior GO:0022401 negative adaptation of signaling pathway GO:0023058 adaptation of signaling pathway GO:0030534 adult behavior GO:0031623 receptor internalization GO:0036465 synaptic vesicle recycling GO:0043112 receptor metabolic process GO:0044708 single-organism behavior GO:0045744 negative regulation of G-protein coupled receptor protein signaling pathway GO:0048013 ephrin receptor signaling pathway GO:0048489 synaptic vesicle transport GO:0050954 sensory perception of mechanical stimulus GO:0051258 protein polymerization GO:0051259 protein oligomerization GO:0051262 protein tetramerization GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0051932 synaptic transmission, GABAergic GO:0060627 regulation of vesicle-mediated transport GO:0061025 membrane fusion GO:0072583 clathrin-dependent endocytosis GO:0090148 membrane fission GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0099003 vesicle-mediated transport in synapse GO:0099504 synaptic vesicle cycle GO:1901998 toxin transport GO:1902803 regulation of synaptic vesicle transport GO:1902805 positive regulation of synaptic vesicle transport GO:1903421 regulation of synaptic vesicle recycling GO:1903423 positive regulation of synaptic vesicle recycling
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0003924 GTPase activity GO:0005525 GTP binding GO:0008017 microtubule binding GO:0008022 protein C-terminus binding GO:0015631 tubulin binding GO:0019001 guanyl nucleotide binding GO:0031749 D2 dopamine receptor binding GO:0032561 guanyl ribonucleotide binding GO:0050780 dopamine receptor binding GO:0050998 nitric-oxide synthase binding
Cellular Component	GO:0001917 photoreceptor inner segment GO:0005874 microtubule GO:0008021 synaptic vesicle GO:0030117 membrane coat GO:0030133 transport vesicle GO:0030424 axon GO:0033267 axon part GO:0043196 varicosity GO:0043209 myelin sheath GO:0044304 main axon GO:0048475 coated membrane GO:0070382 exocytic vesicle GO:0098793 presynapse GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis hsa04721 Synaptic vesicle cycle hsa04961 Endocrine and other factor-regulated calcium reabsorption
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-8856828: Clathrin-mediated endocytosis R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928665: EPH-ephrin mediated repulsion of cells R-HSA-196025: Formation of annular gap junctions R-HSA-190873: Gap junction degradation R-HSA-190828: Gap junction trafficking R-HSA-157858: Gap junction trafficking and regulation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-373760: L1CAM interactions R-HSA-2132295: MHC class II antigen presentation R-HSA-199991: Membrane Trafficking R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-437239: Recycling pathway of L1 R-HSA-177504: Retrograde neurotrophin signalling R-HSA-162582: Signal Transduction R-HSA-166520: Signalling by NGF R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168898: Toll-Like Receptors Cascades R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04144 Endocytosis
hsa04721 Synaptic vesicle cycle
hsa04961 Endocrine and other factor-regulated calcium reabsorption

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-196025: Formation of annular gap junctions
R-HSA-190873: Gap junction degradation
R-HSA-190828: Gap junction trafficking
R-HSA-157858: Gap junction trafficking and regulation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-373760: L1CAM interactions
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-437239: Recycling pathway of L1
R-HSA-177504: Retrograde neurotrophin signalling
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DNM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DNM1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DNM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.312	0.00405
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.577	0.185
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.121	0.24
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.423	0.34
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.313	0.88
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.573	0.846
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.046	0.914
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.042	0.966
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.24	0.84
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.523	0.673
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.301	0.418
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.001	0.996

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DNM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	5.1	-5.1	0.549
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	44.4	0	44.4	0.00996
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	60	0	60	0.0275
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DNM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DNM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DNM1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DNM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DNM1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DNM1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DNM1
Name	dynamin 1
Aliases	DNM; EIEE31; Dynamin-1
Chromosomal Location	9q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DNM1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DNM1